<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content
CDX

HT-1376

Description

HT-1376 (Bladder Cancer CDX Model)

The HT-1376 bladder cancer line was derived from a patient with grade III transitional cell carcinoma. It represents advanced bladder cancer biology. HT-1376 has been applied in drug discovery and biomarker research. Its reproducibility ensures consistent outcomes in bladder cancer translational pipelines.

Key Features:

  • Derived from grade III transitional cell carcinoma.
  • Represents advanced urothelial carcinoma.
  • Epithelial carcinoma morphology.
  • Tumorigenic in xenografts.

Applications:
HT-1376 is used to evaluate novel therapies for bladder cancer. Researchers apply it in biomarker validation and resistance mechanism studies. It supports screening of targeted and cytotoxic agents. Its reproducibility makes it a trusted model for bladder cancer pipelines.

Details
Tumor Type
Bladder
Tumor Subtype
NA
Organism
Human
Mouse Sex
Female
Mouse Strain
Athymic Nude
Mutated Genes
ARID1A
Mutation: p.S186RfsTer209
Effect: Frameshift Variant
*Data provided by DepMap
TERT
Effect: Upstream Gene Variant
Impact: Pathogenic & Likely Pathogenic & Uncertain Significance
*Data provided by DepMap
TP53
Mutation: p.P250L
Effect: Missense Variant
Impact: Uncertain Significance & Likely Pathogenic & Pathogenic / Likely Pathogenic
*Data provided by DepMap
Expression Data (provided by DepMap)
Growth Curve
View on Lumin